Anagliptin vs Trelagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Anagliptin · Suiny

Marketed by Sanwa Kagaku Kenkyusho and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT01529541 · Phase 3 · completed

The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.

Next expected readout: March 2027 · NCT07442006 (registry estimate)

Reported efficacy

The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)

Result source: NCT01529528

Trelagliptin · Zafatek

Marketed by Teijin and partners

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT01431807 · Phase 3 · completed

This was a single-group, open-label study with no randomization, blinding, or comparator arm, despite enrolling 680 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07073768 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)); Number of Participants Who Had One or More Treatment Emergent Adverse Event (TEAE) Before the Start of Study Drug Administration in Treatment Period II (Up to Week 12); Number of Participants Who Had One or More TEAE Occurred After 1st Dose of Trelagliptin 25 mg Tablet (Up to Week 54): Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089) (met)

Result source: NCT02512068

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnagliptinTrelagliptin
HbA1c, change-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
-0.7% vs 0.0%−0.7 vs placebo25 mg · wk 12 · n 55NCT02512068
4 other results
  • -0.7% vs 0.0% 25 mg · wk 12 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6% vs -0.1% 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.5% vs 0.0% 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.2% vs 0.1% 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068
Body weight, change (kg)—Not posted · NCT01529528—Not posted · NCT03940183
HbA1c below 7%—Not posted · NCT01529528—Not posted · NCT03940183
Fasting plasma glucose, change—Not posted · NCT01529528-0.9 vs -0.0−0.9 vs placebo25 mg · wk 12 · n 55NCT02512068
3 other results
  • -0.7 vs -0.2 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6 vs -0.1 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.7 vs 0.1 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068
3-point MACE (% with event)—Not posted · NCT01529528—Not posted · NCT03940183

HbA1c, change

Anagliptin
-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
Trelagliptin
-0.7% vs 0.0%−0.7 vs placebo25 mg · wk 12 · n 55NCT02512068
4 other results
  • -0.7% vs 0.0% 25 mg · wk 12 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6% vs -0.1% 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.5% vs 0.0% 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.2% vs 0.1% 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068

Body weight, change (kg)

Anagliptin
—Not posted · NCT01529528
Trelagliptin
—Not posted · NCT03940183

HbA1c below 7%

Anagliptin
—Not posted · NCT01529528
Trelagliptin
—Not posted · NCT03940183

Fasting plasma glucose, change

Anagliptin
—Not posted · NCT01529528
Trelagliptin
-0.9 vs -0.0−0.9 vs placebo25 mg · wk 12 · n 55NCT02512068
3 other results
  • -0.7 vs -0.2 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6 vs -0.1 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.7 vs 0.1 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068

3-point MACE (% with event)

Anagliptin
—Not posted · NCT01529528
Trelagliptin
—Not posted · NCT03940183
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Anagliptin: 0 of 4 rows · Trelagliptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAnagliptinTrelagliptin
Dropout rate—
21.8%25 mga
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
0%
NCT03014479 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs—
14.5%25 mga
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
0%
NCT03014479 · Phase 4 · registry result, not featured evidence
Serious AEs—
41.8%25 mga
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
1.8%
NCT03014479 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs—
25 mga
nasopharyngitis 43.6% (placebo 33.3%)
fall 21.8% (placebo 10.4%)
hypoglycaemia 21.8% (placebo 14.6%)
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
viral upper respiratory tract infection 3.6%
NCT03014479 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Trelagliptin

HbA1c -0.76% (n=55) vs -0.74% (n=52) placebo @ 52wk25 mg
absolute change · percentage points
At the End of Treatment Period II
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.72 vs 0.13 placebo mmol/L @ 2wk25 mg
absolute change · mmol/L
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -12.9 mg/dL as posted
show 3 more results
-0.63 vs -0.14 placebo mmol/L @ 4wk*25 mg
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -11.3 mg/dL as posted
-0.7 vs -0.24 placebo mmol/L @ 8wk*25 mg
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -12.7 mg/dL as posted
-0.88 vs -0.02 placebo mmol/L @ 12wk*25 mg
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -15.9 mg/dL as posted
Fasting Plasma Glucose -0.79 vs -0.41 placebo mmol/L @ 52wk25 mg
absolute change · mmol/L
At the End of Treatment Period II
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -14.3 mg/dL as posted
DTR-QOL 8.72 vs 6.35 Daily DPP-4 Inhibitors score @ 12wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 2 more results
8.04 vs 4.82 Daily DPP-4 Inhibitors score @ 4wk
NCT03014479 · Phase 4 · registry result, not featured evidence
8.58 vs 6.63 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 1 11.24 vs 7.83 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
10.98 vs 9.12 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 2 5.18 vs 0.39 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
5.94 vs 2.18 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 3 6.15 vs 4.87 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
5.85 vs 7.38 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 4 5.24 vs 3.85 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
8.53 vs 6.71 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTSQs 3.1 vs 1.7 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
3.1 vs 2.9 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Trelagliptin's landscape